Connect with us


Sanofi Buys 4.9% of Novavax for 65 Million Euros

Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter’s valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement for joint marketing of Covid-19 vaccines with flu vaccines. Novavax’s first-quarter revenue increased by 16% to $94 million, while losses decreased by 49.6%.




The French laboratory Sanofi has acquired 4.9% of the shares of the American company Novavax in exchange for $70 million (65 million euros), a price that doubles the company’s valuation to around $1.4 billion ( 1.3 billion euros).

Sanofi’s investment occurs in the context of the co-exclusive licensing agreement reached between the two laboratories for the joint marketing of Covid-19 vaccines in combination with flu vaccines for which the French company will pay up to $1.2 billion ( 1.11 billion euros).

Specifically, Sanofi will make, in favor of the American laboratory, an initial payment of $500 million (465 million euros), in addition to up to another $700 million (650 million euros) depending on development, regulation and milestones.

The terms of the agreement include a co-exclusive license to co-market Novavax’s Covid-19 vaccine worldwide, except in countries with existing advance purchase agreements in place, as well as in India, Japan and South Korea; and an exclusive license for Novavax’s Covid-19 vaccine for use in combination with Sanofi’s flu vaccines.

Including the impact of the agreement with Sanofi, Novavax expects that its annual sales will range between $970 million and 1.17 billion

“We have the opportunity to develop combination vaccines against influenza and Covid-19 without mRNA that offer patients greater comfort and protection against two serious respiratory viruses,” said Jean-François Toussaint, global head of research and development (R&D). D) Sanofi vaccines.

“This collaboration is important for Novavax and for global public health,” said Juan Jacobs, CEO of Novavax. Likewise, the agreement with the French company has allowed Novavax to withdraw its warning about the viability of the business operation ( going concern).

On the other hand, Novavax has reported that in the first quarter of the year its revenue increased by 16%, to $94 million (87 million euros), while the company reduced its losses by 49.6%, to $148 million (137 million euros).

Looking at the year as a whole, the laboratory has cut its annual revenue forecast, excluding the impact of the agreement with Sanofi, to a range of between $400 and $600 million (372 million euros and 558 million), compared to the range previous of between $800 million and $1 billion (743 million euros and 930 million).

However, when including the impact of the agreement with Sanofi, Novavax expects that its annual sales will range between $970 million and 1.17 billion (901 and 1.087 billion euros).


(Featured image by PhotoLizM via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.